APOBECs and Herpesviruses
- PMID: 33671095
- PMCID: PMC7998176
- DOI: 10.3390/v13030390
APOBECs and Herpesviruses
Abstract
The APOBEC family of DNA cytosine deaminases provides a broad and overlapping defense against viral infections. Successful viral pathogens, by definition, have evolved strategies to escape restriction by the APOBEC enzymes of their hosts. HIV-1 and related retroviruses are thought to be the predominant natural substrates of APOBEC enzymes due to obligate single-stranded DNA replication intermediates, abundant evidence for cDNA strand C-to-U editing (genomic strand G-to-A hypermutation), and a potent APOBEC degradation mechanism. In contrast, much lower mutation rates are observed in double-stranded DNA herpesviruses and the evidence for APOBEC mutation has been less compelling. However, recent work has revealed that Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV), and herpes simplex virus-1 (HSV-1) are potential substrates for cellular APOBEC enzymes. To prevent APOBEC-mediated restriction these viruses have repurposed their ribonucleotide reductase (RNR) large subunits to directly bind, inhibit, and relocalize at least two distinct APOBEC enzymes - APOBEC3B and APOBEC3A. The importance of this interaction is evidenced by genetic inactivation of the EBV RNR (BORF2), which results in lower viral infectivity and higher levels of C/G-to-T/A hypermutation. This RNR-mediated mechanism therefore likely functions to protect lytic phase viral DNA replication intermediates from APOBEC-catalyzed DNA C-to-U deamination. The RNR-APOBEC interaction defines a new host-pathogen conflict that the virus must win in real-time for transmission and pathogenesis. However, partial losses over evolutionary time may also benefit the virus by providing mutational fuel for adaptation.
Keywords: APOBEC; DNA cytosine deamination; DNA editing; evolution; herpesvirus; innate antiviral immunity; mutation; restriction factors; ribonucleotide reductase.
Conflict of interest statement
R.S.H. is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc. The other authors have declared that no competing interests exist.
Figures
Similar articles
-
A Conserved Mechanism of APOBEC3 Relocalization by Herpesviral Ribonucleotide Reductase Large Subunits.J Virol. 2019 Nov 13;93(23):e01539-19. doi: 10.1128/JVI.01539-19. Print 2019 Dec 1. J Virol. 2019. PMID: 31534038 Free PMC article.
-
Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity.Nat Microbiol. 2019 Jan;4(1):78-88. doi: 10.1038/s41564-018-0284-6. Epub 2018 Nov 12. Nat Microbiol. 2019. PMID: 30420783 Free PMC article.
-
Human cytomegalovirus mediates APOBEC3B relocalization early during infection through a ribonucleotide reductase-independent mechanism.J Virol. 2023 Aug 31;97(8):e0078123. doi: 10.1128/jvi.00781-23. Epub 2023 Aug 11. J Virol. 2023. PMID: 37565748 Free PMC article.
-
Human APOBEC3 Variations and Viral Infection.Viruses. 2021 Jul 14;13(7):1366. doi: 10.3390/v13071366. Viruses. 2021. PMID: 34372572 Free PMC article. Review.
-
Potential APOBEC-mediated RNA editing of the genomes of SARS-CoV-2 and other coronaviruses and its impact on their longer term evolution.Virology. 2021 Apr;556:62-72. doi: 10.1016/j.virol.2020.12.018. Epub 2021 Jan 7. Virology. 2021. PMID: 33545556 Free PMC article. Review.
Cited by
-
Evidence linking APOBEC3B genesis and evolution of innate immune antagonism by gamma-herpesvirus ribonucleotide reductases.Elife. 2022 Dec 2;11:e83893. doi: 10.7554/eLife.83893. Elife. 2022. PMID: 36458685 Free PMC article.
-
Unveiling the Connection: Viral Infections and Genes in dNTP Metabolism.Viruses. 2024 Sep 3;16(9):1412. doi: 10.3390/v16091412. Viruses. 2024. PMID: 39339888 Free PMC article. Review.
-
The structural basis for HIV-1 Vif antagonism of human APOBEC3G.Nature. 2023 Mar;615(7953):728-733. doi: 10.1038/s41586-023-05779-1. Epub 2023 Feb 8. Nature. 2023. PMID: 36754086 Free PMC article.
-
Functional Domains of the Early Proteins and Experimental and Epidemiological Studies Suggest a Role for the Novel Human Polyomaviruses in Cancer.Front Microbiol. 2022 Feb 18;13:834368. doi: 10.3389/fmicb.2022.834368. eCollection 2022. Front Microbiol. 2022. PMID: 35250950 Free PMC article. Review.
-
Degradation-Independent Inhibition of APOBEC3G by the HIV-1 Vif Protein.Viruses. 2021 Apr 3;13(4):617. doi: 10.3390/v13040617. Viruses. 2021. PMID: 33916704 Free PMC article. Review.
References
-
- Arvin A., Campadelli-Fiume G., Mocarski E., Moore P.S., Roizman B., Whitley R., Yamanishi K., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge University Press; Cambridge, UK: 2007. - PubMed
-
- Kieff E., Rickinson A.B. Epstein-Barr virus and its replication. In: Fields B.N., Knipe D.M., Howley P.M., editors. Fields Virology. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2007. pp. 2603–2654.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous